Histologic distribution of insulin and glucagon receptors [PDF]
Brazilian Journal of Medical and Biological Research, 1998 Insulin and glucagon are the hormonal polypeptides secreted by the B and A cells of the endocrine pancreas, respectively. Their major physiologic effects are regulation of carbohydrate metabolism, but they have opposite effects. Insulin and glucagon have
M. Watanabe +3 more
doaj +5 more sources
Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression [PDF]
Communications Biology, 2021 Abstract Glucagon is a major regulator of metabolism and drugs targeting the glucagon receptor (GCGR) are being developed. Insight into tissue and cell-specific expression of the GCGR is important to understand the biology of glucagon and to differentiate between direct and indirect actions of glucagon.
Anna Billeschou Bomholt +15 more
openaire +5 more sources
Glucagon Receptor Signaling and Glucagon Resistance [PDF]
International Journal of Molecular Sciences, 2019 Hundred years after the discovery of glucagon, its biology remains enigmatic. Accurate measurement of glucagon has been essential for uncovering its pathological hypersecretion that underlies various metabolic diseases including not only diabetes and liver diseases but also cancers (glucagonomas).
Lina Janah +8 more
openaire +3 more sources
The Insulin Receptor Talks to Glucagon? [PDF]
Cell Metabolism, 2009 Type 2 diabetes (T2DM) is not only a disorder of impaired insulin secretion but also glucagon oversecretion. However, the link between the two remains unclear. Is it possible that the latter is a consequence of the former? In this issue, Kawamori et al. (2009) have addressed this question by generating alpha cell-specific insulin receptor knockout mice.
Gromada, J, Duttaroy, A, Rorsman, P
openaire +3 more sources
Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice [PDF]
Molecular Metabolism, 2022 Treatment with glucagon receptor antagonists (GRAs) reduces blood glucose but causes dyslipidemia and accumulation of fat in the liver. We investigated the acute and chronic effects of glucagon on lipid metabolism in mice.Chronic effects of glucagon receptor signaling on lipid metabolism were studied using oral lipid tolerance tests (OLTTs) in ...
Galsgaard, Katrine D. +16 more
openaire +4 more sources
Variation in responses to incretin therapy: Modifiable and non-modifiable factors
Frontiers in Molecular Biosciences, 2023 Type 2 diabetes (T2D) and obesity have reached epidemic proportions. Incretin therapy is the second line of treatment for T2D, improving both blood glucose regulation and weight loss.
Gregory O. Austin, Alejandra Tomas
doaj +1 more source
Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro [PDF]
, 2003 The growth rate of numerous cancer cell lines is regulated in part by actions of neuropeptides of the vasoactive intestinal peptide (VIP) family, which also includes pituitary adenylate cyclase-activating peptide (PACAP), glucagon, and peptide histidine ...
Alleaume, Céline +4 more
core +1 more source
What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands [PDF]
, 2019 Dipeptidyl peptidase 4 (DPP4) is an exopeptidase found either on cell surfaces where it is highly regulated in terms of its expression and surface availability (CD26) or in a free/circulating soluble constitutively available and intrinsically active form.
Aguilar-Pérez, Alexandra +13 more
core +1 more source
Treatment of type 2 diabetes by free fatty acid receptor agonists [PDF]
, 2014 Dietary free fatty acids (FFAs), such as ω-3 fatty acids, regulate metabolic and anti-inflammatory processes, with many of these effects attributed to FFAs interacting with a family of G protein-coupled receptors.
Hudson, Brian D. +3 more
core +2 more sources
Photoaffinity labeling of the glucagon receptor with a new glucagon analog [PDF]
European Journal of Biochemistry, 1984 The preparation, purification and characterization of N‐4‐azidophenylamidinoglucagon are described. This photoreactive peptide was found to be 50% as potent as native glucagon in competing with 125I‐labeled glucagon for binding to glucagon receptors on rat liver plasma membranes. Similarly, the analog was 50% as potent as native glucagon in its ability
D E, Wright, R, Horuk, M, Rodbell
openaire +2 more sources